Syngene
Offers integrated therapeutic discovery and development services, including R&D and manufacturing, with a focus on collaboration and sustainability.
Overview
Syngene provides a comprehensive platform called SynVent for integrated therapeutic discovery and development, catering to both large and small molecules. This platform supports emerging biopharma companies working in innovative disease areas with limited data and regulatory guidance.
The company operates Dedicated Centers that feature multi-disciplinary scientific teams and customized infrastructure to meet specific client R&D goals. These centers are designed to facilitate collaboration and innovation in research and development.
Syngene's Centre for Advanced Protein Studies (CAPS) in Bangalore is a state-of-the-art facility that enhances their research capabilities. Additionally, the company offers various certificate programs in biosciences and applied industrial microbiology, empowering young faculty and professionals in the life sciences field.
Recognized as one of the "World's Most Sustainable Companies, 2025" by TIME Magazine and Statista, Syngene is committed to sustainability in its operations. The company is expanding its bioreactor capacity to 50,000 liters, further enhancing its manufacturing capabilities.
Syngene provides end-to-end solutions for R&D and manufacturing, fostering client relationships that go beyond traditional outsourcing. Their Discovery Services cover early-stage research, while Development Services span from pre-clinical to clinical trials. Manufacturing services include cGMP-compliant facilities for clinical supplies and registration batches.
Syngene InstaVisit offers an interactive virtual experience, allowing clients to explore their world-class facilities and capabilities through a guided tour.
- Collaborations with top 20 Pharma/Biotech companies
- Extensive R&D and manufacturing infrastructure
- Numerous patents and active client engagements